BD Helps Scientists Advance Immunology and Cancer Research with AI-Powered Insights and Automation
Rhea-AI Summary
BD (NYSE: BDX) announced the global commercial release of BD Research Cloud 7.0 on January 23, 2026, introducing BD Horizon Panel Maker, an AI-powered tool for automated panel design to support immunology and cancer research.
The cloud-based platform supports collaboration, workflow streamlining and lab operations management, and the new AI tool generates optimized panel recommendations within seconds from custom inputs or curated validated databases. The release highlights integrated visualization features (comparison tables and complexity scores) and explicit support for imaging and spectral panel design with BD FACSDiscover instruments. BD Research Cloud 7.0 is commercially available at bdresearchcloud.com.
Positive
- Global commercial release of BD Research Cloud 7.0 on January 23, 2026
- BD Horizon Panel Maker delivers AI-generated panel recommendations within seconds
- Integrated imaging and spectral panel design support with BD FACSDiscover instruments
- Cloud ecosystem enables collaboration, workflow streamlining, and lab operations management
Negative
- None.
News Market Reaction
On the day this news was published, BDX declined 2.06%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed, mostly modest moves: ALC +0.11%, BAX +0.5%, while RMD -2.54%, WST -3.28%, HOLX -0.13%, indicating this AI-focused update was stock-specific rather than a sector-wide driver.
Previous AI Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 20 | AI platform launch | Positive | +1.0% | Launched BD Incada connected care and AI-enabled Pyxis Pro solutions. |
| Apr 21 | AI monitoring launch | Positive | -1.1% | Introduced HemoSphere Alta with AI-driven hemodynamic decision support. |
Prior AI-related launches produced relatively small one-day moves with mixed direction, suggesting measured market responses to BD’s AI announcements.
Recent AI-focused news from BD shows a steady build-out of smart, connected solutions. On Oct 20, 2025, BD introduced the BD Incada™ Connected Care Platform and next-gen BD Pyxis™ Pro, supporting data from nearly 3 million devices and processing about 9.8 million transactions per day, and shares moved about +1%. On Apr 21, 2025, BD launched the AI-driven HemoSphere Alta™ hemodynamic monitoring platform, but the stock slipped roughly -1.06%. Today’s BD Research Cloud 7.0 update continues that AI roadmap in life sciences and flow cytometry.
Historical Comparison
Prior AI-tagged launches saw modest one-day moves averaging about 1.03%, indicating historically contained reactions to BD’s AI product news.
AI-tagged news has progressed from hospital connectivity and medication management to advanced monitoring and now cloud-based research tools in flow cytometry.
Market Pulse Summary
This announcement extends BD’s AI roadmap into research workflows, using BD® Research Cloud 7.0 and BD Horizon™ Panel Maker to streamline flow cytometry panel design. Historically, AI-tagged launches have led to relatively modest one-day moves averaging about 1.03%. In the background, BD reported record fiscal 2025 revenue of $21.8 billion and adjusted EPS of $14.40, while planning a $2.5 billion U.S. manufacturing investment and a Reverse Morris Trust transaction expected to generate about $4 billion in cash.
Key Terms
flow cytometry medical
spectral panel design technical
AI-generated analysis. Not financial advice.
Newest version of BD® Research Cloud features an AI-powered tool for automated panel design to improve quality, efficiency and usability of scientific results across research areas
BD® Research Cloud version 7.0 provides scientists with a cloud-based ecosystem for flow cytometry that supports collaboration between team members, streamlines workflows, and manages laboratory operations, from instrument health to purchasing and managing reagents.
The new BD Horizon™ Panel Maker tool leverages a novel, sophisticated AI algorithm to generate optimized panel recommendations within seconds. Researchers can create panels using custom experimental inputs or draw from curated databases of validated options. Poorly designed panels can lead to unusable, unreliable or irreproducible data, resulting in wasted time, samples, and reagents. By providing automated recommendations and integrated visualization tools, like comparison tables and complexity scores, BD Horizon™ Panel Maker enables researchers to more efficiently evaluate and select the panels best suited for their experiments.
"By harnessing the power of AI, the new version of BD® Research Cloud is engineered to help scientists reach high-quality scientific insights in a fraction of the time, while reducing complexity and potential for error," said Steve Conly, worldwide president, BD Biosciences. "This new AI tool also unlocks the full potential of our BD FACSDiscover™ Cell Analyzer and Cell Sorters, letting researchers get the most out of both cutting-edge hardware and software, for even the most complex experiments."
BD Horizon™ Panel Maker is the only commercially available tool that supports integrated imaging and spectral panel design when working with BD FACSDiscover™ Instruments.
BD® Research Cloud version 7.0 with BD Horizon™ Panel Maker is now available at bdresearchcloud.com. More information is available at bdbiosciences.com.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts: | |
Media: | Investors: |
Fallon McLoughlin | Adam Reiffe |
Director, Public Relations | VP, Investor Relations |
201.258.0361 | 201.847.6927 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-helps-scientists-advance-immunology-and-cancer-research-with-ai-powered-insights-and-automation-302668624.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
What did BD (BDX) announce on January 23, 2026 about BD Research Cloud 7.0?
How does BD Horizon Panel Maker speed up panel design for researchers using BDX products?
Does BD Research Cloud 7.0 support BD FACSDiscover instruments for imaging and spectral panel design?
Where can researchers access BD Research Cloud 7.0 and BD Horizon Panel Maker?
What laboratory functions does BD Research Cloud 7.0 manage for life sciences teams?
